Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Harrow, of Nashville, Tennessee reported Nov. 13 that it had entered into a partnership with GoodRx to provide patients without insurance or for whom insurance is not a viable option a cash-pay alt...
Israel’s Novoxel announced Nov. 19 that the US FDA had granted 510(k) clearance to the Tixel i treatment device for evaporative dry eye and meibomian gland dysfunction. The company said the device ...
UK-headquartered Immunocore reported Nov. 6 that its Q3-2024 net revenue from Kimmtrak (tebentafusp) was $80.2 million, a 28 percent increase over $62.6 million in Q3-2023. Regionally, Kimmtrak net...
Aldeyra Therapeutics announced Nov. 18 that the US FDA had accepted for review the company’s resubmitted new drug application (NDA) for topical ocular reproxalap for dry eye. The FDA assigned a Pre...
Alcon reported Nov. 12 that its Q3-2024 net sales totaled $2.4 billion, a 6 percent increase over $2.3 billion in Q3-2023. Surgical net sales for implantables, consumables, and equipment/other were...
ARPA-H announced Oct. 18 that it had launched a new program to develop a tear-based biomarker measurement system that can be inserted into the tear duct to provide continuous health monitoring, pai...
NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...
Heidelberg Engineering announced Oct. 14 that the US FDA had granted 510(k) clearance to its Flex Module for the Spectralis diagnostic imaging platform. The Flex Module mounts the Spectralis to a m...
AbbVie, of North Chicago, Illinois, reported Oct. 30 that its Q3-2024 eye care net revenue was $525 million, a 13.5 percent decline (-11.2 percent cc) from $605 million in Q3-2023. Restasis revenue...
NovaBay reported Nov. 6 that it had accepted a higher offer from PRN Physician Recommended Nutriceuticals, LLC, which revised its bid for NovaBay’s Avenova product line after a competing overture f...
Tarsus Pharmaceuticals, maker of Xdemvy for Demodex blepharitis, announced Nov. 5 that it had appointed Elizabeth Yeu, MD, as chief medical officer. Yeu had served as Tarsus’ chief medical advisor ...
NovaBay reported Oct. 29 that it had received a better offer for its assets than the one it had accepted from PRN Physician Recommended Nutriceuticals, LLC. NovaBay’s board determined that the unso...
ARPA-H announced Oct. 18 that it had launched a new program to develop a tear-based biomarker measurement system that can be inserted into the tear duct to provide continuous health monitoring, pai...
Barcelona-basedGrifols reported Oct. 22 that it is partnering with the US government’s BARDA to test ocular surface immunoglobulin (OSIG) eye drops for their ability to treat ocular damage from sul...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Oculus has announced the addition of frequency doubling perimetry (FDP) to its Easyfield VR visual field diagnostic headset. The German ophthalmic diagnostic company, with US headquarters in Arling...
NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRN Physician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close...
Aldeyra Therapeutics announced Oct. 3 that it had resubmitted its new drug application (NDA) to the US FDA for topical ocular reproxalap in dry eye. The US FDA issued a complete response letter in ...
Germany’s Novaliq announced Oct. 2 that the European Commission had approved its dry eye treatment Vevizye (cyclosporine ophthalmic solution) 0.1%. The product is indicated for the treatment of mod...
NovaBay Pharmaceuticals has agreed to sell its Avenova products to PRNPhysician Recommended Nutriceuticals for $9.5 million in cash, the companies announced Sept. 20. The deal is expected to close ...
The US FDA has sent a warning letter to Regenerative Processing Plant in Palm Harbor, Florida, finding fault with its manufacturing processes and raising concerns that its eye drop products may sti...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Eyenovia announced in its Q2-2024 financial results that it planned to seek marketing clearance for an advanced Gen-2 Optejet microdoser. Eyenovia, of New York, said production was expected to begi...
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
MeiraGTx led recent ophthalmic fundraising efforts with a $50 million offering of ordinary shares as it moves forward with its extensive pipeline of gene therapy candidates. Financing announced in ...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...
Ireland-based Mallinckrodt announced Aug. 6 that its H.P. Acthar Gel single-dose prefilled SelfJect injector was available in the US. The US FDA approved the supplemental new drug application for t...
China’s Ocumension Therapeutics announced Aug. 13 that it would acquire or secure Chinese rights to a portfolio of Alcon dry eye treatments and procedural drops. In exchange, Ocumension will issue ...
AbbVie, of North Chicago, Illinois, reported July 25 that Q2-2024 net revenue for its eye care products totaled $533 million, a 13.3 percent decline (-10.9 percent cc) from $617 million in Q2-2023....
Japan-based Hoya Corporation announced Aug. 1 that its medical care segment (IOLs, endoscopes, artificial bone) had revenue for the quarter ending June 30, 2024—the first quarter of its fiscal year...
Richard Weise, MD, and his wife, Cathy, have gifted their ophthalmic practice, the Glendale Eye Medical Group, of Glendale, California, to the USC Roski Eye Institute, the university announced July...
Taiwan-based Formosa Pharmaceuticals announced Aug. 5 that it had agreed to license to Apotex exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical inflammation and pain...
Regeneron, of Tarrytown, New York, reported Aug. 1 that its Q2-2024 US revenue for Eylea was $1.53 billion, a 2 percent increase from $1.5 billion in Q2-2023. Eylea HD accounted for $304 million of...
Germany’s Novaliq announced July 29 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for Vevi...
Eyenovia, of New York, announced July 30 that it had entered into a collaboration agreement with SGN Nanopharma to develop SGN’s micellar nanoparticle platform-based cyclosporine formulation for us...
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
Eyenovia, of New York, announced July 23 that it had entered into a collaboration agreement with Japan’s Senju Pharmaceutical to develop Senju’s corneal epithelial wound healing candidate, SJP-0035...
AbbVie has introduced two new preservative-free lubricant eye drop products—Refresh Tears PF and Refresh Relieva PF Xtra. AbbVie, of North Chicago, Illinois, said the new products feature a soft-sq...
Bausch + Lomb is expanding its fast-growing consumer segment with the launch of a nutritional supplement to combat the signs and symptoms of dry eye. The supplement is called Blink NutriTears. The ...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Bausch + Lomb announced July 23 that it had acquired dry eye diagnostic company Trukera Medical from its private equity owner, AccelMed Partners, and other shareholders. No financial details were d...
London’s Okyo Pharma announced July 11 that it would advance OK-101 into a Phase II clinical trial of neuropathic corneal pain (NCP). The US FDA cleared the investigational new drug (IND) applicati...
Kane Biotech announced June 25 that I-Med Pharma had licensed its DispersinB biofilm dispersion technology to incorporate into its products to relieve dry eye. It’s the first commercial agreement f...
Nordic Pharma announced May 29 that it had launched Lacrifill canalicular gel for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative intended to temporarily block tear draina...
BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Japan’s Nidek announced June 3 that it had launched the RS-1 Glauvas OCT system. The device is CE marked as a Class IIa device. Nidek said the RS-1 Glauvas’ streamlined workflow and advanced analyt...
BioTissue announced June 3 that it was launching the CAM360 AmnioGraft, a new hydrated, shelf-stable cryopreserved amniotic membrane product for mild to moderate dry eye and other ocular surface di...
Nordic Pharma announced May 29 that it had launched Lacrifill canalicular gel for dry eye in the US. Lacrifill is a cross-linked hyaluronic acid derivative intended to temporarily block tear draina...
Santen has issued a voluntary recall and suspended shipment for all unexpired lots of its dry eye treatment Diquas LX in Japan due to issues with a preservative, Pharma Japan reported May 23. Sante...
AbbVie, of North Chicago, Illinois, reported April 26 that its Q1-2024 eye care net revenue totaled $538 million, an 11.7 percent decline (-10.4 percent cc) from $608 million in Q1-2023. Restasis r...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Taiwan-based Formosa Pharmaceuticals announced May 9 that it had entered into an exclusive licensing agreement with Tabuk Pharmaceuticals to market clobetasol propionate 0.05% eye drops for post-su...
Alcon reported May 13 that its Q1-2024 net sales were $2.4 billion, a 5 percent increase (+7 percent cc) over $2.3 billion in Q1-2023. Surgical net sales totaled $1.34 billion, consisting of $433 m...
Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 that its Q1-2024 US net product revenue for Syfovre was $137.5 million, compared with $18.4 million in Q1-2023. Syfovre gained US ...
France’s Lumibird Medical announced May 3 that it had launched C.Diag, a dry eye diagnostic imaging platform incorporating artificial intelligence, after gaining the European Union’s CE marking for...
Bausch + Lomb reported May 1 that its Q1-2024 revenue was $1.1 billion, an 18 percent increase (+20 percent cc) over $931 million in Q1-2023. Vision Care segment revenue in Q1-2024 was $635 million...
The need to continue lobbying for dry eye evaluation prior to patients undergoing anterior segment surgery is somewhat baffling. Such testing seems like an obvious approach for the many patients wh...
A nor’easter storm that disrupted many travel itineraries failed to deter the nearly 600 industry personnel and clinicians who attended Eyecelerator ahead of the 2024 ASCRS meeting. This year’s con...
Alexion, the rare disease unit of AstraZeneca, announced March 25 that the US FDA had approved its long-acting C5 complement inhibitor Ultomiris (ravulizumab-cwvz) for adults with neuromyelitis opt...
Aldeyra Therapeutics on March 28 outlined its new clinical development plan for reproxalap eye drops, with the goal of resubmitting its new drug application (NDA) to the US FDA. The company said it...
Iridex, of Mountain View, California, reported March 26 that its 2023 revenue was $51.9 million, a 9 percent decrease from $57 million in 2022. Cyclo G6 product revenue was $13.4 million, a 9 perce...
London’s Okyo Pharma released additional findings on March 22 from its Phase II trial of topical dry eye candidate OK-101. The company had previously reported statistically significant improvements...
Nashville, Tennessee-based Harrow reported March 19 that its 2023 revenue was $130.2 million, a 47 percent increase over $88.6 million in 2022. The company generated record quarterly revenue in Q4-...
Amring Pharmaceuticals announced March 4 that it had changed its name to Nordic Pharma Inc., following the change in ownership of the company from Sever Life Sciences to Nordic Group in June 2023. ...
India’s Brassica Pharma announced Feb. 12 that it was voluntarily recalling eye ointments sold by retailers such as Walmart and CVS due to a danger of infection. The company said an inspection by t...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Ocular Therapeutix led recent ophthalmic fundraising efforts with a $325 million private placement to advance its candidate for wet age-related macular degeneration. Financing announced in the past...
Germany’s VSY Biotechnology launched its Enova Maestro trifocal toric preloaded intraocular lens (IOL) at the European Society of Cataract and Refractive Surgeons (ESCRS) Winter Meeting, held Feb. ...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Sight Sciences reported March 7 that it generated 2023 total revenue of $81.1 million, an increase of 14 percent over $71.3 million in 2022. Surgical glaucoma revenue in 2023 was $74.3 million, a 1...
Eyenovia and NovaBay Pharmaceuticals announced March 13 the signing of a co-promotion agreement to commercialize their prescription ophthalmic products. Under the agreement, NovaBay will market Eye...
Surface Ophthalmics, of Pleasanton, California, has named co-founder and director Richard Lindstrom, MD, as chairman. The company, which is developing dry eye drugs, was formed in 2018. Lindstrom w...
Vital Tears announced March 6 that it had appointed Joseph Tauber, MD, as its chief medical officer. In 2023, Vital Tears added mobile phlebotomy services to its system of providing autologous seru...
Tarsus Pharmaceuticals, of Irvine, California, announced March 1 that it had priced an underwritten public offering of shares and warrants, with expected gross proceeds of $100 million. Goldman Sac...
Alcon reported Feb. 27 that its full year 2023 net sales totaled $9.4 billion, an 8 percent increase (+10 percent cc) over $8.7 billion in 2022. Q4-2023 sales were $2.3 billion, an 8 percent increa...
India’s Brassica Pharma announced Feb. 12 that it was voluntarily recalling eye ointments sold by retailers such as Walmart and CVS due to a danger of infection. The company said an inspection by t...
Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Amneal Pharmaceuticals announced Jan. 10 that it had received US FDA approval for and launched generic fluorometholone eye drops. The product is indicated for the treatment of corticosteroid-respon...
Harrow reported Feb. 15 that it had licensed to Apotex exclusive marketing and distribution rights to Verkasia and over-the-counter Cationorm Plus in the Canadian market. In addition, Apotex will p...
Chinese biotech company LianBio announced Feb. 13 that it would wind down operations—including selling its pipeline assets, delisting its American Depositary Shares from the Nasdaq, and cutting its...
Spain’s Sylentis, a PharmaMar Group company, announced Feb. 9 that tivanisiran, a topical treatment candidate for dry eye disease associated with Sjögren’s syndrome, did not meet primary efficacy e...
Regeneron, of Tarrytown, New York, reported Feb. 2 that its 2023 US revenue for Eylea 2 mg (aflibercept 2 mg) and Eylea HD (aflibercept 8 mg) totaled $5.9 billion, a 6 percent decline from $6.3 bil...
Bausch + Lomb made a flurry of big moves in 2023, with product approvals, acquisitions, leadership changes, and strategic partnerships and collaborations following the company’s IPO in mid-2022. In...
The US FDA granted five clearances through the ophthalmic device division using the 510(k) pathway in December 2023, according to the agency’s database. RetMap gained market clearance for its RM El...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Makers of over-the-counter eye drops came under increased surveillance from the US FDA in 2023, in part because contaminated products manufactured in India caused at least 81 people to become infec...
The US FDA approved a new class of drugs to treat the signs and symptoms of dry eye disease in 2023. Two new treatments in the class, Miebo and Vevye, are both based on perfluorocarbon (PFC) molecu...
Alcon reported Jan. 9 that it saw positive topline results from two pivotal Phase III clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512 in dry eye. AR-15512, a TR...
China’s Ji Xing Pharmaceuticals led recent ophthalmic fundraising efforts with $162 million in Series D funding to advance its pipeline, which includes five ophthalmic candidates. Financing announc...
Maker of Sophi Phaco Machines UK-based Rayner announced Jan. 17 that it had acquired Switzerland’s This AG, the maker of Sophi phacoemulsification machines. No financial details were disclosed. Sop...
Harrow, of Nashville, Tennessee, reported Jan. 11 that dry eye drugVevye is now available in the US. Vevye (cyclosporine ophthalmic solution) 0.1% is a non‑preserved, twice-daily-dosed prescription...
Alcon reported Jan. 9 that it saw positive topline results from two pivotal Phase III clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512 in dry eye. AR-15512, a TR...
Nordic Pharma subsidiary Amring Pharmaceuticals announced Dec. 18 that it had completed its acquisition of Visant Medical. Visant received US FDA 510(k) clearance in 2022 for its Lacrifill cross-li...
Tarsus Pharmaceuticals, of Irvine, California, reported Dec. 11 that TP-03 (lotilaner ophthalmic solution, 0.25%) saw positive topline results in the Phase IIa Ersa trial of patients with meibomian...
Aldeyra Therapeutics reported Nov. 27 that the US FDA had, as expected, issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment fo...
The US FDA has released its preliminary report of an inspection conducted Oct. 12-20 at Kilitch Healthcare India, manufacturer of 27 over-the-counter eye drop products that were recalled Nov. 13 du...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
2023 was a busy year for the US FDA in ophthalmology. Among the 11 drug products approved were the first two therapies in the US to treat geographic atrophy; two new drops for dry eye; and a second...
Aldeyra Therapeutics reported Nov. 27 that the US FDA had, as expected, issued a complete response letter rejecting the company’s new drug application (NDA) for topical reproxalap as a treatment fo...
The US FDA has released its preliminary report of an inspection conducted Oct. 12-20 at Kilitch Healthcare India, manufacturer of 27 over-the-counter eye drop products that were recalled Nov. 13 du...
Online retailer Amazon has removed seven eye drop products from its site after the US FDA warned the company that the products were unapproved drugs, making claims to relieve conjunctivitis or floa...
Dry eye revenue continues to fall in the US this year, despite new products, as generic cyclosporine ophthalmic solutions and emulsions increase market share at the expense of brand name Restasis. ...
EyeBio led recent ophthalmic fundraising efforts with $65 million in Series A funding to continue development of its candidate for retinal disease. Financing announced in the past four weeks totale...
Dry Eye: New products kept generating buzz around dry eye. Bausch + Lomb leaned into the promotion of Miebo, the new, first-in-class drug therapy that directly targets tear evaporation. Diagnostic ...
Eyecelerator awarded a total of $45 thousand in prize money to winning pitch challengers at its fall meeting, after emerging companies got a chance to work with accomplished industry veterans to re...
Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...
The US FDA issued a warning to consumers Oct. 27 to immediately stop using more than two dozen over-the-counter eye drop products due to the potential risk of blinding eye infections. The products ...
Specialty pharma company Padagis announced Oct. 13 the launch of its brinzolamide ophthalmic suspension, a generic version of Novartis’ Azopt for glaucoma. Padagis, with offices in the US and Israe...
UK-headquartered Immunocore reported Nov. 7 that its Q3-2023 net revenue from Kimmtrak (tebentafusp) was £49.7 million ($60.7 million, converted at a rate of £1.00 to $1.2214), an increase of 9 per...
Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2023—its fiscal year Q2-2023—of ¥33.5 billi...
Regeneron of Tarrytown, New York, reported Nov. 2 that its Q3-2023 US revenue for Eylea (aflibercept) 2 mg and Eylea HD (a higher dose of aflibercept at 8 mg) was $1.49 billion, with Eylea HD accou...
Aldeyra Therapeutics announced Nov. 1 that AbbVie had signed an exclusive option agreement to license to develop, manufacture, and commercialize reproxalap, Aldeyra’s candidate in development for d...
The US FDA issued a warning to consumers Oct. 27 to immediately stop using more than two dozen over-the-counter eye drop products due to the potential risk of blinding eye infections. The products ...
Bruder Healthcare, of Alpharetta, Georgia, announced Oct. 20 that it had added a single-use, air-activated moist heat mask to its line of dry eye relief products. Bruder said the Eyedration mask be...
Swiss company Roche reported Oct. 19 that Q3-2023 Vabysmo sales were CHF 656 million ($732 million, converted Oct. 19), a 309 percent increase over CHF 173 million in Q3-2022. Vabysmo was approved ...
Ophthalmic deals in Q3-2023 reached nearly $2.8 billion and involved 22 transactions. This compares with $6.9 billion from 24 transactions in Q2-2023 and $1.0 billion from 20 transactions in Q3-202...
France’s Tilak Healthcare led recent ophthalmic fundraising efforts with a $10.6 million funding round for its medical video games for chronic vision disorders. Financing announced in the past four...
Minimally Invasive Glaucoma Surgery (MIGS): The ESCRS highlighted the growing importance of MIGS this year by holding the meeting’s first MIGS master class. Several speakers in other sessions extol...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Théa Pharma, the US subsidiary of France’s Laboratoires Théa, announced the launch Sept. 26 of once-daily Iyuzeh (latanoprost ophthalmic solution) 0.005% in the US market. Iyuzeh is the first prese...
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
Sight Sciences, of Menlo Park, California, has informed its employees that it will cut its workforce of 250 by 25 employees as it awaits a final decision by five of the seven Medicare Administrativ...
Aldeyra Therapeutics reported in a securities filing on Oct. 16 that the US FDA had found “substantive” issues with the company’s new drug application (NDA) for topical dry eye candidate reproxalap...
Merakris Therapeutics unveiled its Opticyte Tears program on Oct. 12—offering to deliver personalized autologous serum tears in less than two hours, without patients ever having to leave home. Mera...
London-based CS Pharmaceuticals reported July 28 that it had acquired AxeroVision, of Carlsbad, California, and its AXR-270 candidate for dry eye disease. The company did not report financial detai...
Mati Therapeutics, of Austin, Texas, reported Sept. 12 that it had completed a 10 thousand square foot facility in Bryan, Texas, to manufacture the company’s Evolute sustained drug delivery platfor...
Bausch + Lomb announced Sept. 12 the US launch of Miebo (perfluorohexyloctane ophthalmic solution) for dry eye disease. The US FDA approved Miebo in May for dosing four times daily. Bausch + Lomb a...
The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...
Brim Biotechnologies, of Taiwan, led recent ophthalmic fundraising efforts with a $45.8 million rights issue to advance its lead dry eye candidate. Funding announced in the past four weeks totaled ...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Carl Zeiss Meditec announced Aug. 23 that more than 8 million eyes had been treated with the company’s SMILE procedure through the first half of 2023. SMILE, short for small-incision lenticule extr...
Bausch + Lomb announced Sept. 12 the US launch of Miebo (perfluorohexyloctane ophthalmic solution) for dry eye disease. The US FDA approved Miebo in May for dosing four times daily. Bausch + Lomb a...
The US FDA reported Sept. 12 that it had issued warning letters to eight companies for manufacturing or marketing unapproved eye drug products, expanding the list of companies that the FDA has targ...
Link Biologics, of London, and France’s Théa Open Innovation announced Sept. 12 that they had agreed to co-develop Link’s topical anti-inflammatory candidate TSG6 for dry eye disease and other opht...
Viatris, of Pittsburgh, reported Aug. 7 that its Tyrvaya nasal spray for dry eye accounted for net sales of $10.2 million in Q2-2023. The prescription treatment posted net sales of $6.3 million in ...
The US FDA issued a warning on Aug. 22 telling consumers not to purchase and to immediately stop using Dr. Berne’s MSM Drops 5% Solution and LightEyez MSM Eye Drops—Eye Repair due to bacterial cont...
AbbVie, of North Chicago, Illinois, reported July 27 that Q2-2023 net revenue for its eye care products totaled $617 million, a 13.9 percent decline from $717 million in Q2-2022. Restasis revenue w...
Novaliq, of Heidelberg, Germany, announced Aug. 24 that the European Medicines Agency (EMA) had accepted its marketing authorization application for dry eye candidate CyclASol (cyclosporine ophthal...
Tarsus Pharmaceuticals announced July 25 that the US FDA had approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the ...
Kriya Therapeutics led recent ophthalmic fundraising efforts with $150 million in a Series C financing to advance its gene therapy candidates. Funding announced in the past four weeks totaled $456....
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...
Taiwan-based Formosa Pharmaceuticals announced Aug. 16 that Eyenovia had licensed US rights to Formosa’s APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) for inflammation and pain ...
Tarsus Pharmaceuticals announced July 31 that it had commenced an underwritten public offering of $100 million in common stock. The Irvine, California, company said it would grant the underwriters ...
Tarsus Pharmaceuticals announced July 25 that the US FDA had approved Xdemvy (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis. Xdemvy, formerly known as TP-03, is the ...
Swiss company Roche reported July 27 that Vabysmo sales for Q2-2023 were CHF 525 million ($606 million, converted July 27, 2023), a nearly 500 percent increase over CHF 88 million in Q2-2022. Roche...
Brent Saunders seems to be betting that what was good for Allergan’s eye care business will be good for Bausch + Lomb. Dry eye treatments dominated Allergan’s eye care business during Saunders’ ten...
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic prescription and biologic drug candidates and those classified as drug/device combin...
Japanese drugmaker Santen announced July 18 that Harrow had acquired US or Canadian commercial rights to seven of Santen’s branded eye drops, while Visiox Pharma had licensed US rights to Omlonti f...
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.